LETTER TO THE EDITOR

Prognostic Utility of Baseline 25-Hydroxy Vitamin D Levels in Hospitalised COVID-19 Patients: Hope or Hype?

Sir,

Coronavirus disease 2019 (COVID-19) has caused more than 745,000 deaths globally.¹ A vital challenge for healthcare providers amidst the pandemic is the absence of scientific evidence signifying effective pharmacologic interventions for prevention and cure.² The 25-Hydroxy Vitamin D (25-OH-D) has been widely utilised as a potential strategy to prevent or treat COVID-19 disease. A review of randomised controlled trials from 2007 to 2020 has shown protective role of 25-OH-D against acute respiratory infections; however, considerable limitations and heterogeneity exist.³

The “sunny” vitamin’s deficiency affects over one billion people worldwide, and a population-based study from Pakistan reported 53.5% deficiency along with 31.2% insufficiency.⁴ Currently, there is no clear evidence especially from Pakistan, with a high prevalence of deficiency, on the prognostic utility of 25-OH-D. After approval from the Ethical Review Committee (ERC#2020-5168-14099), we retrospectively reviewed the data from the electronic health records of polymerase chain reaction-proven COVID-19 patients, to evaluate the association of 25-OH-D with severity of infection and mortality from March to August, 2020.

Table I: Distribution of age and 25-hydroxy vitamin D levels in the two study groups.

<table>
<thead>
<tr>
<th>Group</th>
<th>Age (mean +/- SD)</th>
<th>25-OH-vitamin D (median IQR)</th>
<th>p-value*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Severe cases (n=4)</td>
<td>65 +/- 3.6 years</td>
<td>19.5 (13.9-21.3) ng/ml</td>
<td>0.05</td>
</tr>
<tr>
<td>Non-severe cases (n=7)</td>
<td>44.3 +/- 17.9 years</td>
<td>18.7 (15-45) ng/ml</td>
<td>0.788</td>
</tr>
<tr>
<td>Non-survivors (n=2)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Survivors (n=9)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (mean +/- SD)</td>
<td>64.5 +/- 4.5 years</td>
<td>21.1 (20.8-21.1) ng/ml</td>
<td>0.27</td>
</tr>
<tr>
<td>25-OH-vitamin D (median IQR)</td>
<td></td>
<td>18.1 (13.8-37.5) ng/ml</td>
<td>0.582</td>
</tr>
</tbody>
</table>

*P-value <0.05 considered significant.

The 25-OH-D test was undertaken within 24 hours of admission in only 11/239 COVID-19 in-patients (4.7%), with a male predominance (n=7). Taking 30 ng/ml as the cut off for 25-OH-D deficiency, 8 (73%) were found deficient. Furthermore, the data was split into two categories based on severity and survival. The two quantitative variables i.e. age and 25-OH-D levels were compared between groups using t-test and Mann-Whitney U-test, respectively, as depicted in Table I.

Increasing age was the only variable associated with severity of infection (p=0.05); whereas, no significant differences were noted for 25-OH-D in the two categories.

From a laboratory test requisition perspective, only 4.7% had baseline test requested amongst 239 COVID-19 cases. This further reflects that the clinicians were also not inclined towards its evaluation, in spite of the fact that Vitamin D metabolites have long been known to support innate immunity and antiviral effector mechanisms.

Despite limitations of a small subgroup with available 25-OH-D levels, this study concludes that contrary to the claims that 25-OH-D deficiency is associated with disease progression, including some recommending potentially toxic doses, no significant utility of 25-OH-D exists. However, large-scale longitudinal studies are required to establish its role; it is too early to recommend its inclusion in the standard biochemical workup of COVID-19 cases.

CONFLICT OF INTEREST:
The authors declared no conflict of interest.

AUTHORS’ CONTRIBUTION:
SA: Devised the idea, analysed the data, literature review and penned the letter.
LJ: Involved in letter writing review of literature and analyses.

REFERENCES

Sibtain Ahmed and Lena Jafri
Department of Pathology, The Aga Khan University Hospital, Karachi, Pakistan
